Electronic Drug Delivery Systems Global Market Report 2024

The electronic drug delivery systems market has grown strongly in recent years. It will grow from $10.54 billion in 2023 to $11.45 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The expansion observed in the historical period can be ascribed to an increased incidence of chronic diseases, a growing aging population, patient preferences favoring non-invasive delivery methods, efforts to contain healthcare costs, and advancements in clinical practices and validation.

The electronic drug delivery systems market is expected to see strong growth in the next few years. It will grow to $16.12 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The anticipated growth in the forecast period can be linked to the upward trend in drug personalization, the escalation of global healthcare expenditure, the adoption of a patient-centric healthcare approach, the emergence of targeted therapies, a supportive regulatory environment, and advancements in remote patient monitoring. Key trends expected in the forecast period involve the integration of artificial intelligence (AI), the utilization of biocompatible materials and implantable devices, customization tailored to specific therapeutic areas, regulatory advancements and standardization, as well as collaborations between pharmaceutical and technology companies.

The anticipated growth of the electronic drug delivery systems market is expected to be driven by the increasing prevalence of chronic diseases. Chronic diseases, lasting for more than a year and necessitating ongoing medical treatment, can benefit from electronic drug delivery systems that aid in regulating and monitoring drug doses. For example, in January 2023, the National Library of Medicine reported that the number of individuals in the US aged 50 and older with at least one chronic condition is projected to reach 142.66 million by 2050. This upward trend in chronic diseases is poised to fuel the demand for electronic drug delivery systems.

The growth of the electronic drug delivery systems market is also anticipated to be propelled by the increasing investment in healthcare facilities. Investment in healthcare facilities involves financial commitments for acquiring, developing, upgrading, or maintaining infrastructure, equipment, technology, and other resources essential for healthcare service provision. Investments in electronic drug delivery systems contribute valuable data on medication administration, enabling real-time monitoring and analytics. This empowers healthcare providers to make informed decisions, identify trends, and optimize treatment plans based on patient responses. For instance, as reported by The Moscow Times, Russia's federal project on modernizing primary healthcare plans to allocate 88.8 billion rubles ($910 million) in 2023 and 550 billion rubles ($5.7 billion) for 2023-25. Consequently, the increasing investment in healthcare facilities is a significant driver of the electronic drug delivery systems market's growth.

A prominent trend in the electronic drug delivery system market is the development of technologically advanced and minimally invasive drug delivery systems. Leading companies in the electronic drug delivery market are introducing innovative and technologically sophisticated drug delivery systems to maintain their competitive positions. For example, in March 2022, Evonik Industries AG, a Germany-based specialty chemicals company, unveiled EUDRATEC SoluFlow, a novel microparticle technology designed to enhance the solubility of active pharmaceutical ingredients in oral drug products. This technology, part of the company's oral drug delivery portfolio, is aimed at addressing diseases such as cancer, cardiovascular diseases, infectious diseases, and diabetes.

Major companies are strategically forming partnerships and collaborations with startups and mid-sized companies in the electronic drug delivery system market to expand their product and service offerings. Strategic partnerships involve collaborative relationships between two or more organizations to achieve specific business objectives or goals. For instance, in October 2022, Nemera, a France-based company specializing in the development and manufacturing of drug delivery device solutions for the pharmaceutical, biotechnology, and generic industries, announced a partnership with Zollner Elektronik AG. This strategic alliance enhances both Nemera and Zollner's capabilities, combining expertise in drug delivery devices and the pharmaceutical industry with electronics development and manufacturing knowledge in the medical industry. Zollner Elektronik AG is a Germany-based provider of Electronic Drug Delivery Systems services.

In March 2022, Sandoz, a Switzerland-based pharmaceutical company, completed the acquisition of Coalesce Product Development Limited for an undisclosed amount. This acquisition equips Sandoz with Coalesce's capabilities, enhancing the company's existing portfolio of respiratory medicines and high-quality, complex therapies. Coalesce Product Development Limited is a UK-based medical and drug delivery device development company.

Major companies operating in the electronic drug delivery systems market report are Gerresheimer AG, Amgen Inc., Medtronic plc, Novo Nordisk A/S, Insulet Corporation, Bayer AG, AstraZeneca plc, Tandem Diabetes Care, Merck KGaA, United Therapeutics Corporation, F. Hoffmann-La Roche AG, Elcam Medical, Sanofi S.A., Canè SpA, FindAir, Johnson & Johnson Services Inc., Antares Pharma Inc., Abbott Laboratories, Adherium Ltd., H&T Presspart Manufacturing Ltd., HCmed Innovations Co. Ltd., Amiko Digital Health Limited, CeQur Corporation, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Holozymes Inc., West Pharmaceutical Services Inc., Pfizer Inc., Novartis AG, BIOCORP.

North America was the largest region in the electronic drug delivery systems market in 2023. Asia-pacific is expected to be the fastest-growing region in the global electronic drug delivery systems market report during the forecast period. The regions covered in the electronic drug delivery systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the electronic drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of electronic drug delivery systems include electronic infusion pumps, electronic injection pens, electronic auto-injectors, electronic inhalers, electronic capsules, and other variants. Electronic infusion pumps are medical devices that regulate the controlled delivery of fluids into a patient's body. Deployed in healthcare settings such as hospitals and nursing homes, these pumps are instrumental in delivering fluids such as nutrients and medications. Essential components of electronic drug delivery systems comprise sensors, wireless communicators, antennas, micro-pumps, flow regulators, drug reservoirs, microcontrollers, and other elements, available in both battery-powered and rechargeable systems. These electronic drug delivery systems are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, catering to the treatment of various conditions such as diabetes, cardiovascular disease, respiratory disorders, multiple sclerosis, and other ailments.

The electronic drug delivery systems market research report provides electronic drug delivery systems market statistics, including electronic drug delivery systems industry global market size, regional shares, competitors with an electronic drug delivery systems market share, detailed electronic drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the electronic drug delivery systems industry. This electronic drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The electronic drug delivery systems market consists of sales of nasal sprays, eyedroppers, and intrauterine devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.